As of today, there are more than a dozen OAd-based vectors that were or are currently under investigation for breast cancer treatments including Ad3-hTERT-E1A [35], Onyx-015 [36], Telomelysin [37], ColoAd1 [38], VCN-01 [39], H103 [40], VISTA [41], Ad HSV-tk [42], Ad5/3 delta 24 GMCSF [43,44], Ad5/3 E2F delta 24 GMCSF [45], Ad5 delta 24 GMCSF [46,47], Ad5 RGD delta 24 GMCSF [48], and ICOVIR-7 [49]. This evidence concerns the gene DHTKD1 and breast carcinoma.